Skip to main content

CRG Partners III L.P.'s Form 4 filing

T2 Biosystems, Inc. (TTOO) · filed Sep 27, 2023

Accession no.
0001209191-23-050677
Filed
Sep 27, 2023, 5:53 PM ET
Trade date
Sep 25, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions. Open-market sales total $62.5K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
CRG Partners III L.P.CIK 000163759110% Owner
CRG Partners III - Parallel Fund (A) L.P.CIK 000165135710% Owner
CR Group L.P.CIK 000170235210% Owner
CRG Partners III (Cayman) Lev AIV I L.P.CIK 000176750910% Owner
CRG Partners III (Cayman) Unlev AIV I L.P.CIK 000176751010% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 25, 2023Common StockSSaleDisposed−99,979$0.25−$24,994.757,407,678Indirect
Sep 25, 2023Common StockSSaleDisposed−62,258$0.25−$15,564.54,612,840Indirect
Sep 25, 2023Common StockSSaleDisposed−19,996$0.25−$4,9991,481,535Indirect
Sep 25, 2023Common StockSSaleDisposed−67,767$0.25−$16,941.755,021,014Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)